Initial Single-center Experience of PIPAC in Patients With Unresectable Peritoneal Metastasis

INTRODUCTIONPeritoneal carcinomatosis remains a condition with poor prognosis and limited therapeutic options. Pressurized Intrapertioneal Aerosol Chemotherapy (PIPAC) has been developed as a new tool for delivering intraperitoneal chemotherapy with low morbidity. The aim of this study was to evalua...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cirugia española (English ed.) 2021-05, Vol.99 (5), p.354-360
Hauptverfasser: Cuadrado Ayuso, Marta, Cabañas Montero, Jacobo, Priego Jiménez, Pablo, Corral Moreno, Sara, Longo Muñoz, Federico, Pachón Olmos, Vanesa, Fernández Cebrián, José María, Galindo Álvarez, Julio
Format: Artikel
Sprache:eng ; spa
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:INTRODUCTIONPeritoneal carcinomatosis remains a condition with poor prognosis and limited therapeutic options. Pressurized Intrapertioneal Aerosol Chemotherapy (PIPAC) has been developed as a new tool for delivering intraperitoneal chemotherapy with low morbidity. The aim of this study was to evaluate the initial experience of PIPAC in patients with peritoneal carcinomatosis at our hospital. METHODSA prospective study between January 2019 and February 2020 was carried at a tertiary public hospital. Primary tumor, ascites volume, PCI, chemotherapy regimen, operative time, morbidity, length of hospital stay and mortality were recorded for analysis. RESULTSWe analyzed 9 PIPAC procedures performed in 5patients. Median PCI was 27.6 (24-35). Median surgical time was 93minutes (70-125). Only one adverse event occurred out of 9 procedures (Clavien-DindoII). Median length of hospital stay was 2days (1-4). Mortality was 0%. CONCLUSIONPIPAC seems to be a feasible and safe procedure to treat peritoneal carcinomatosis, with low morbidity and short hospital stay.
ISSN:2173-5077
DOI:10.1016/j.ciresp.2020.06.020